Tim Cook says Apple doesn't intend to license Masimo's blood oxygen detection patents to end the US' Apple Watch import ban, and is instead “focused on appeal”
Wesley Hilliard / AppleInsider :
Context & Ripple Effects
Masimo's patent dispute with Apple began with a 2020 lawsuit alleging infringement involving blood-oxygen and heart-rate technology. After the administration declined to intervene in the ITC import decision, Apple explored a software workaround rather than immediately settling; CBP later indicated sales could resume with pulse oximetry disabled.
Cook's position makes the legal route central to Apple's response: the company had a potential feature-disabled sales path, while a later court filing shows it continued to pursue reversal of the ITC decision.
First-order effects
- Apple will pursue an appeal rather than pay Masimo for a patent license, leaving the import restriction—and the availability of blood-oxygen functionality—subject to the dispute's legal and administrative outcomes.
- Masimo retains its patent-enforcement leverage, while Apple can rely on the CBP-approved removal of pulse oximetry as an alternative route to selling affected watches.
Second-order effects
- The dispute forces Apple to weigh product-feature continuity against the cost and precedent of a licensing settlement; it also makes patent clearance more consequential for health-feature roadmaps.
- The case tests whether an ITC exclusion order can be managed through software changes, following reports that Apple was developing a software workaround despite Masimo's contention that hardware changes were needed.
Third-order effects
- If appeals and design-around strategies become the preferred response to wearable-health patent disputes, feature availability may become more fragmented by market and legal jurisdiction.
- The episode underscores how medical-technology patents can shape consumer-device competition: enforcement can constrain a flagship feature even without resolving the broader commercial conflict.
The trend: Wearable makers are increasingly treating health-sensor intellectual property as a product-access and regulatory-risk issue, not merely a licensing cost.